Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–26 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Poorly Differentiated Neuroendocrine Carcinomas Clear all

Completed Phase 1 Interventional

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023

View directory record Official record

Conditions: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: 90Y-DOTA-tyr3-OCTREOTIDE; Radiation
Lead sponsor: O'Dorisio, M S; Other
Eligibility: 2 Years to 25 Years

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Source: ClinicalTrials.gov public record

Updated Jun 20, 2016 · Synced May 22, 2026, 2:49 AM EDT

Recruiting Phase 2Phase 3 Interventional

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

NCT05058651

View directory record Official record

Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 244
States / cities: Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 188 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 22, 2026, 2:49 AM EDT